SCIOSCIA, CRESCENZIO
 Distribuzione geografica
Continente #
NA - Nord America 5.358
AS - Asia 1.636
EU - Europa 1.531
SA - Sud America 381
Continente sconosciuto - Info sul continente non disponibili 157
AF - Africa 56
OC - Oceania 5
Totale 9.124
Nazione #
US - Stati Uniti d'America 5.265
SG - Singapore 735
IT - Italia 379
CN - Cina 345
BR - Brasile 298
SE - Svezia 268
RU - Federazione Russa 226
HK - Hong Kong 186
DE - Germania 172
FR - Francia 154
GB - Regno Unito 97
FI - Finlandia 90
VN - Vietnam 89
IN - India 56
BD - Bangladesh 54
CA - Canada 51
BE - Belgio 39
AR - Argentina 36
IQ - Iraq 26
MX - Messico 25
UA - Ucraina 23
TR - Turchia 20
PL - Polonia 18
CI - Costa d'Avorio 16
ID - Indonesia 16
SA - Arabia Saudita 15
ZA - Sudafrica 15
CO - Colombia 12
IR - Iran 12
JP - Giappone 12
EC - Ecuador 11
PK - Pakistan 11
IE - Irlanda 10
NL - Olanda 10
UZ - Uzbekistan 10
CZ - Repubblica Ceca 9
VE - Venezuela 9
ES - Italia 8
MY - Malesia 8
PH - Filippine 8
AT - Austria 6
CL - Cile 6
PY - Paraguay 6
LT - Lituania 5
NP - Nepal 5
OM - Oman 5
AU - Australia 4
AZ - Azerbaigian 4
ET - Etiopia 4
TH - Thailandia 4
TN - Tunisia 4
AL - Albania 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
KE - Kenya 3
MA - Marocco 3
RS - Serbia 3
AE - Emirati Arabi Uniti 2
DZ - Algeria 2
GR - Grecia 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
PA - Panama 2
PS - Palestinian Territory 2
SN - Senegal 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BY - Bielorussia 1
CH - Svizzera 1
EE - Estonia 1
EU - Europa 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
JO - Giordania 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MM - Myanmar 1
MN - Mongolia 1
MP - Marianne Settentrionali, isole 1
MT - Malta 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
PE - Perù 1
PR - Porto Rico 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TG - Togo 1
ZW - Zimbabwe 1
Totale 8.970
Città #
Ashburn 671
Fairfield 487
Chandler 449
Singapore 406
Woodbridge 326
San Jose 311
Seattle 270
Houston 265
Ann Arbor 254
Nyköping 227
Cambridge 197
Hong Kong 185
Wilmington 164
Milan 152
Beijing 150
New York 81
Council Bluffs 73
Dearborn 68
Dallas 66
Los Angeles 65
Munich 63
Lawrence 62
Roxbury 62
Jacksonville 61
Rome 56
Lauterbourg 54
Helsinki 44
Des Moines 39
Inglewood 39
Santa Clara 39
Brussels 38
Brooklyn 36
Moscow 36
Nanjing 34
Ho Chi Minh City 32
Paris 31
São Paulo 29
Bari 27
San Diego 27
Turku 26
Boardman 24
London 23
Princeton 19
Buffalo 17
Redwood City 17
Toronto 17
Warsaw 17
Abidjan 16
Atlanta 16
Chicago 16
Hanoi 16
Hebei 16
Orem 16
Figino 14
Montreal 14
Poplar 13
Columbus 12
Denver 12
Frankfurt am Main 11
Mumbai 11
San Francisco 11
Washington 11
Stockholm 10
The Dalles 10
Tokyo 10
Boston 9
Dublin 9
Falkenstein 9
Shenyang 9
Tashkent 9
Baghdad 8
Brasília 8
Naples 8
Quito 8
San Mateo 8
Shanghai 8
Turin 8
Belo Horizonte 7
Campinas 7
Guangzhou 7
Mexico City 7
Ottawa 7
Riyadh 7
Amsterdam 6
Chennai 6
Haiphong 6
Hefei 6
Jakarta 6
Jiaxing 6
Jinan 6
Johannesburg 6
Kunming 6
Manchester 6
Ardabil 5
Augusta 5
Bogotá 5
Brno 5
Changsha 5
Charlotte 5
Da Nang 5
Totale 6.309
Nome #
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 203
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 193
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 190
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 189
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 188
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 185
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 185
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 175
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 174
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 173
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 172
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 171
AB0369 Adult-onset still’s disease treatment predictors at 1-year follow-up in a single rheumatologic centre experience 170
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 161
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 159
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 157
Diffusion and applications of musculoskeletal ultrasound in Italian Rheumatology Units 153
A knowledge-based framework enabling decision support in RFID solutions for healthcare 153
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 151
Old and new antirheumatic drugs and the risk of hepatotoxicity 151
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 150
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 148
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 147
AB1114 Three Years Experience with “Sustain”, an Extra-Hospital Infusion Programme for Patients with Rheumatoid Arthritis Treated with Abatacept 146
Infliximab therapy in patients with rheumatic disease and HCV chronic infection 144
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 139
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 139
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 137
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 137
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 134
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 133
Integrin expression on human osteoblasts in osteoarthritis 133
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 130
Osteocalcin production by osteoarthritic osteoblasts after vitamin D stimulation 127
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 126
The italian MSUS study group recommendations for the format and content of the report and documentation in musculoskeletal ultrasonography in rheumatology 123
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 122
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 121
Ultrasonography in the diagnosis and management of patients with inflammatory arthritides 120
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 120
SAT0380 FIBROMYALGIA IS THE STRONGEST NEGATIVE PREDICTOR FOR THE ACHIEVEMENT OF EITHER REMISSION AND MINIMAL DISEASE ACTIVITY IN NAIVE PSORIATIC ARTHRITIS PATIENTS STARTING BIOLOGIC DRUGS 118
COMP serum levels in patients with rheumatoid arthritis before and after infliximab therapy 114
OP0217 Ultrasound-Detected Synovitis and Tenosynovitis Independently Associate with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 113
SAT0061 Concurrent Ultrasound-Detected Synovitis and Tenosynovitis Predict Flare in Patients with Rheumatoid Arthritis in Clinical Remission 111
Plasma pentraxin 3 in idiopathic inflammatory myopathies: a possible new biomarker of disease activity 106
Economical Evaluation of the Sustain Program for the Out-of-Hospital Administration of Abatacept for Rheumatoid Arthritis 103
null 101
Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: Results by Italian DELphi in psoriatic arthritis (IDEA) 99
The treatment of recurrent uveitis with TNF-alpha inhibitors 98
null 97
Leukocytoclastic vasculitis as onset symptom of ulcerative colitis 96
Increased Bcl-2/p53 ratio in human articular cartilage: a possible role in regulation of chondrocyte metabolism 95
Correction to: Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) (Clinical Rheumatology, (2018), 37, 3, (667-675), 10.1007/s10067-018-3989-2) 92
Musculoskeletal ultrasonography for psoriatic arthritis and psoriasis patients: A systematic literature review 89
Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission 87
Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey 87
Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis 86
null 84
null 82
null 82
Ultrasonography in psoriatic arthritis: Which sites should we scan? 82
null 79
Influence of TNF- α inhibition on oxidative stress of rheumatoid arthritis patients 79
Ultrasound-detected tenosynovitis independently associates with patient-reported flare in patients with rheumatoid arthritis in clinical remission: Results from the observational study STARTER of the Italian Society for Rheumatology 74
Use of etanercept in the treatment of dermatomyositis: a case series 73
null 73
Repeated infusions of low-dose infliximab plus methotrexate in psoriathic arthrtritis: immediate benefitis are not maintained after discontinuation of inlfiximab 69
L'obésité diminue le maintien thérapeutique des traitements biologiques de seconde ligne après échec d'un anti-TNF de première ligne au cours de la polyarthrite rhumatoïde 69
null 66
The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: The STARTER study 63
Use of ultrasound in treatment decisions for patients with rheumatoid arthritis: an observational study in Italy 60
null 53
Power Doppler signal at the enthesis and bone erosions are the most discriminative OMERACT ultrasound lesions for SpA: results from the DEUS (Defining Enthesitis on Ultrasound in Spondyloarthritis) multicentre study 47
null 46
null 45
null 44
Turning the Tide against Herpes Zoster in Rheumatoid Arthritis Patients Treated with JAK Inhibitors 33
Totale 9.124
Categoria #
all - tutte 36.613
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 36.613


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022449 0 0 0 25 26 40 15 23 24 44 79 173
2022/20231.034 114 150 82 116 113 130 29 108 144 10 23 15
2023/2024252 18 57 15 22 19 59 4 13 4 8 2 31
2024/20251.250 24 21 101 44 12 100 120 167 54 78 198 331
2025/20262.695 398 114 124 247 374 179 279 63 341 201 66 309
2026/2027616 54 94 218 250 0 0 0 0 0 0 0 0
Totale 9.124